

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **GLOBAL HEMP GROUP INC.** (the "Issuer").

Trading Symbol: **GHG**

Number of Outstanding Listed Securities: **24,291,458**

Date: **April 3, 2024**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company is focused on two business segments:

- **INDUSTRIAL HEMP:** This division is focused on, but not limited to, the carbon negative use of hemp-based construction materials and carbon neutral bio-energy sources.
- **BIOPHARMA:** The Health and Wellness Division is acquiring exclusive licensing of patents and other IP. To date the Company has executed agreements for partnerships with companies like B-Organic R&D Corp. and Apollon Formularies plc.

The Company continues to work on expanding both these segments with additional opportunities and people to assist in developing its business segments.

GHG also continues to work on closing the remaining \$377,500 balance of its previously announced \$445,000 non-brokered unit private placement. Each unit consists of one common share of the company at \$0.05 per share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share of the company at an exercise price of \$0.10 until January 15, 2027.

The Company continues to work with B-Organic R&D Corp. to conclude an agreement relating to the exclusive licensing of its Bioactive Lipid Agents (BLA) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous poorly soluble pharma ingredients, including cannabinoids.

Management Cease Trade Order ("MCTO") - On January 30, 2024 the Company announced that it anticipated a delay in the filing of its audited financial statements and Management's Discussion and Analysis ("Required Filings"). GHG was granted an MCTO under National Policy 12-203 Management Cease Trade Orders by the British Columbia Securities Commission, as principal regulator for the Company. The MCTO will restrict all trading by the Company's CEO and CFO in securities of the Company, whether direct or indirect. The issuance of the MCTO will not affect the ability of persons who are not directors, officers or insiders of the Company to trade their securities. The MCTO will remain in effect until the Required Filings are filed or

until it is revoked or varied. The Company expects that the Required Filings will be completed and filed on or before April 12, 2024, as extended by the BCSC.

2. Provide a general overview and discussion of the activities of management.
See #1 above.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
NONE
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
None
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
None
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
None
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
None
8. Describe the acquisition of new customers or loss of customers.
None
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. **None**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **None**
11. Report on any labour disputes and resolutions of those disputes if applicable.
None
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the

proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued/returned to treasury, and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A			

⁽¹⁾ State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 3, 2024.

Curt Huber
Name of Director or Senior Officer

"Curt Huber"
Signature

Director
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer Global Hemp Group Inc.		March 2024	YY/MM/DD 2024/04/03
Issuer Address #106 – 1169 Mt. Seymour Road			
City/Province/Postal Code North Vancouver, BC V7H 2Y4		Issuer Fax No. N/A	Issuer Telephone No. 778-726-2900
Contact Name Curt Huber		Contact Position Director	Contact Telephone No. 778-726-2900
Contact Email Address info@globalhempgroup.com		Web Site Address www.globalhempgroup.com	